<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2110211206
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EPITAM 250 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        59.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Epitam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). Epitam is used:</p><ul><li>On its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat partial onset seizures with or without secondary generalisation.</li><li>As an add-on to other antiepileptic medicines to treat:&nbsp;</li></ul><p>- partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age</p><p>- myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy</p><p>- primary generalised tonic-clonic seizures in adults and Adolescentsfrom 12 years of age with idiopathic generalized epilepsy</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Epitam&reg;</strong>&nbsp;</p><ul><li>If you are allergic (hypersensitive) to levetiracetam or any of the other ingredients of this medicine (listed in Section 6).</li></ul><p><strong>Warnings and precautions&nbsp;</strong></p><p>Talk to your doctor before taking Epitam</p><ul><li>If you suffer from kidney problems, follow your doctor&rsquo;s instructions. He/she may decide if your dose should be adjusted.</li><li>If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor.</li><li>If you notice an increase in seizure severity (e.g. increased number), please contact your doctor.</li><li>A small number of people being treated with anti-epileptics such as Epitam have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.</li></ul><p><strong>Other medicines and Epitam&reg;</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Epitam&reg; with food and drink</strong><br />You may take Epitam with or without food. As a safety precaution, do not take Epitam with alcohol.</p><p><strong>Pregnancy and breast-feeding</strong><br />Ask your doctor or pharmacist for advice before taking any medicine.</p><p>If you are pregnant or if you think you may be pregnant, please inform your doctor.</p><p>Epitam should not be used during pregnancy unless clearly necessary. A risk of birth defects for your unborn child cannot be completely excluded. Epitam has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures. Breast-feeding is not recommended during treatment.</p><p><strong>Driving and using machines</strong><br />Epitam may impair your ability to drive or operate any tools or machinery, as Epitam may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Epitam must be taken twice a day, once in the morning and once in the evening, at about the same time each day.</p><p>Take the number of tablets following your doctor&rsquo;s instructions.&nbsp;</p><p><strong>Monotherapy</strong></p><ul><li>Dose in adults and adolescents (from 16 years of age): General dose: between 1000 mg and 3,000 mg each day.</li></ul><p>When you will first start taking Epitam, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest general dose.</p><p>Example: if your daily dose is 1000 mg, you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening.</p><p><strong>Add-on therapy</strong></p><ul><li>Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more: General dose: between 1,000 mg and 3,000 mg each day.</li></ul><p>Example: if your daily dose is 1,000 mg, you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening.</p><ul><li>Dose in infants (6 to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:</li></ul><p>Your doctor will prescribe the most appropriate pharmaceutical form of Epitam according to the age, weight and dose. Epitam 100 mg/ml oral solution is a presentation more appropriate to infants and children under the age of 6 years.</p><p>General dose: between 20 mg per kg bodyweight and 60 mg per kg body weight each day. Example: a general dose of 20 mg per kg body weight each day, you might give your 25 kg child 1 tablet of 250 mg in the morning and 1 tablet of 250 mg in the evening.</p><ul><li>Dose in infants (1 month to less than 6 months):</li></ul><p>Epitam 100 mg/ml oral solution is a presentation more appropriate to infants.</p><p><strong>Method of administration:</strong><br />Swallow Epitam tablets with a sufficient quantity of liquid (e.g. a glass of water).</p><p><strong>Duration of treatment:</strong></p><ul><li>Epitam is used as a chronic treatment. You should continue Epitam treatment for as long as your doctor has told you.</li><li>Do not stop your treatment without your doctor&rsquo;s advice as this could increase your seizures. Should your doctor decide to stop your Epitam treatment, he/she will instruct you about the gradual withdrawal of Epitam.&nbsp;</li></ul><p><strong>If you take more Epitam&reg; than you should</strong><br />The possible side effects of an overdose of Epitam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.</p><p>Contact your doctor if you took more tablets than you should. Your doctor will establish the best possible treatment of overdose.</p><p><strong>If you forget to take Epitam&reg;&nbsp;</strong><br />Contact your doctor if you have missed one or more doses. Do not take a double dose to make up for a forgotten tablet.&nbsp;</p><p><strong>If you stop taking Epitam&reg;</strong><br />If stopping treatment, as with other antiepileptic medicines, Epitam should be discontinued gradually to avoid an increase of seizures.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of the side effects like sleepiness, tiredness and dizziness may be more common at the beginning of the treatment or at dose increase. These effects should however decrease over time.</p><p><strong>Very common side effects (may affect more than 1 in 10 people):</strong></p><ul><li>Nasopharyngitis;</li><li>Somnolence (sleepiness), headache.</li></ul><p><strong>Common side effects (may affect up to 1 to 10 users in 100):</strong></p><ul><li>Anorexia (loss of appetite);</li><li>Depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;</li><li>Convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy, tremor (involuntary trembling);</li><li>Vertigo (sensation of rotation);</li><li>Cough;</li><li>Abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;</li><li>Rash;</li><li>Asthenia/fatigue (tiredness).</li></ul><p><strong>Uncommon side effects (may affect up to 1 to 10 users in 1000):</strong></p><ul><li>Decreased number of blood platelets, decreased number of white blood cells;</li><li>Weight decrease, weight increase;</li><li>Suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;</li><li>Amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);</li><li>Diplopia (double vision), vision blurred;</li><li>Liver function test abnormal;</li><li>Hair loss, eczema, pruritus;</li><li>Muscle weakness, myalgia (muscle pain);</li><li>Injury.</li></ul><p><strong>Rare side effects (may affect up to 1 to 10 users in 10,000 people):</strong></p><ul><li>Infection;</li><li>Decreased number of all blood cell types;</li><li>Severe hypersensitivity reactions (DRESS);</li><li>Decreased blood sodium concentration;</li><li>Suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);</li><li>Uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);</li><li>Pancreatitis;</li><li>Hepatic failure, hepatitis;</li><li>Skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens&ndash; Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Do not use Epitam&reg; after the expiry date which is stated on the carton after &ldquo;Exp&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is called levetiracetam.</p><p>One tablet of Epitam 250 mg contains 250 mg of levetiracetam. One tablet of Epitam 500 mg contains 500 mg of levetiracetam. One tablet of Epitam 750 mg contains 750 mg of levetiracetam.</p><p>The other ingredients are:<br />Tablet core: croscarmellose sodium, Povidone k-30, microcrystalline cellulose, magnesium stearate.</p><p>Film-coating: Opadry white, colourants*.</p><p>* The colourants are:<br />500 mg tablet: iron oxide yellow (E172)<br />750 mg tablet: iron oxide yellow, iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Epitam tablets are foiled with PVC/PVDC aluminum foil.

Epitam 250 mg film-coated tablets are white, capsule shape, scored and debossed with the code “JI 175” on one side.

Epitam 500 mg film-coated tablets are yellow, capsule shape, scored and debossed with the code “JI 176” on one side.

Epitam 750 mg film-coated tablets are light pink, capsule shape, scored and debossed with the code “JI 177” on one side.

Pack size: 30 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jazeera Pharmaceutical Industries (JPI)</p><p>Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229</p><p>Phone No.: +966-11-207-8172</p><p>Fax: +966-11-207-8097</p><p>E-mail: medical@jpi.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 10/2015, version 1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ابيتام هو دواء مضاد للصرع (دواء يستخدم لعلاج التشنجات في الصرع).</p><p>يستخدم ابيتام:<br />&bull; كعلاج وحيد عند البالغين والمراهقين من 16 سنة من العمر ممن تم تشخيصهم حديثا الصرع، لعلاج بداية النوبات الجزئية مع أو دون التعميم الثانوي.<br />&bull; كعلاج اضافي مع الأدوية الأخرى المضادة للصرع لعلاج:<br />- ظهور نوبات جزئية مع أو بدون تعميم في البالغين والمراهقين والأطفال والرضع من الشهر الأول من العمر<br />- نوبات رمعية في البالغين والمراهقين من 12 سنة من العمر يعانون من الصرع رمعية الأحداث<br />- النوبات الأولية المعممة التوترية الارتجاجية في البالغين و المراهقين من 12 سنة من العمر مع الصرع المعمم مجهول السبب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تأخذ ابيتام</strong></p><ul><li>إذا كنت تعاني من حساسية (فرط الحساسية)&nbsp;للفتيراسيتام أو أي من المكونات الأخرى من هذا الدواء (المدرجة في القسم 6).</li></ul><p><strong>التحذيرات والاحتياطات</strong><br />تحدث مع طبيبك قبل استعمال ابيتام</p><ul><li dir="rtl">إذا كنت تعاني من مشاكل في الكلى، اتبع تعليمات طبيبك الخاص. انه/انها قد يقرر ما إذا كان ينبغي تعديل الجرعة</li><li dir="rtl">إذا لاحظت أي تباطؤ في النمو أو تطور في بلوغ غير متوقع لطفلك، يرجى الاتصال بالطبيب.</li><li dir="rtl">إذا لاحظت زيادة في شدة التشنجات (على سبيل المثال زيادة عددها)، يرجى الاتصال بالطبيب.</li><li dir="rtl">وهناك عدد قليل من المرضى الذين يعالجون بالأدوية المضادة للصرع مثل ابيتام تنتابهم أفكار بإيذاء أو قتل أنفسهم. إذا كان لديك أي أعراض للاكتئاب و/أو التفكير في الانتحار، يرجى الاتصال بالطبيب.&nbsp;</li></ul><p><strong>استعمال الأدوية الأخرى مع ابيتام&reg;</strong><br />يرجى إخبار الطبيب أو الصيدلي إذا كنت تأخذ أو لديك اتخذت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية تم الحصول عليها من دون وصفة طبية.<br />&nbsp;</p><p><strong>ابيتام&reg; مع الطعام والشراب</strong><br />يمكنك تناول ابيتام مع أو بدون الطعام. وكإجراء احترازي، لا تأخذ ابيتام مع الكحول.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />إسأل طبيبك أو الصيدلي للحصول على المشورة قبل اتخاذ أي دواء.</p><p>إذا كنت حاملاً&nbsp;أو إذا كنت تعتقد أنك قد تكون حاملاً، يرجى إبلاغ الطبيب.</p><p>ابيتام لا ينبغي أن تستخدم خلال فترة الحمل ما لم تكن الحاجة اليه ملحَه. خطر العيوب الخلقية للأطفال الذين لم يولدوا بعد لا يمكن استبعادها تماما. وقد أظهر ابيتام خلال التجارب على الحيوان نتائج غير مرغوبة عند جرعات عالية لاتحتاجها لمعالجة تشنجاتك.</p><p>لا ينصح بالرضاعة الطبيعية أثناء العلاج.</p><p><strong>القيادة واستخدام الآليات</strong><br />ابيتام قد تضعف قدرتك على القيادة أو تشغيل أي أدوات أو الآلات، كما قد يجعلك ابيتام تشعر بالنعاس. لاسيما عند بداية العلاج أو بعد زيادة في جرعة. يجب أن لا تشغل أو تستخدم الآلات حتى تتم استعادة قدرتك على أداء هذه الأنشطة بما لايتنافى مع حالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استعمل دائما هذا الدواء تماما كما وصفه لك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكد.</p><p>جرعة ابيتام يجب أن تؤخذ مرتين في اليوم، مرة في الصباح ومرة واحدة في المساء، في الوقت نفسه تقريبا من كل يوم.</p><p>تناول عدد الأقراص المطلوبه حسب إرشادات الطبيب.</p><p><strong>المعالجة الأحادية</strong></p><ul><li>الجرعة عند البالغين والمراهقين (من 16 سنة من العمر):</li></ul><p>الجرعة المعتادة: بين 1000 ملغ و3000 ملغ كل يوم.</p><p>عند بداية العلاج بابيتام، سوف يصف لك طبيبك جرعة أقل لمدة اسبوعين وذلك قبل اعطائك جرعتك المعتادة.</p><p>مثال: إذا الجرعة اليومية هي 1000 ملغ، قد تأخذ 2 حبة من 250 ملغ في الصباح و2 حبة من 250 ملغ في المساء.</p><p><strong>إضافة ابيتام مع غيره من العلاجات</strong></p><ul><li>الجرعة في البالغين والمراهقين (12-17&nbsp;سنة) والوزن 50 كجم أو أكثر:</li></ul><p>الجرعة المعتادة: بين 1000 و3000&nbsp;ملغ&nbsp;كل يوم.</p><p>مثال: إذا الجرعة اليومية هو 1000 ملغ، قد تأخذ 2 حبة من 250 ملغ في الصباح و 2 حبة من 250 ملغ في المساء.</p><ul><li dir="rtl">الجرعة عند الرضع (6-23 شهراً) والأطفال (2-11 سنوات) والمراهقين (12-17 سنة) أوزانهم أقل من 50 كلغ:&nbsp;</li></ul><p>طبيبك سوف يصف الشكل الصيدلاني الأنسب لابيتام وفقاً&nbsp;للعمر والوزن والجرعة. ابيتام 100&nbsp;ملغ/مل للحل عن طريق الفم هي أكثر ملامة للرضع والأطفال الذين تقل أعمارهم عن 6 سنوات.&nbsp;</p><p>الجرعة المعتادة: بين 20 ملغ لكل كيلوغرام من وزن الجسم، و60&nbsp;ملغ لكل كيلوغرام من وزن الجسم كل يوم.<br />المثال: الجرعة المطلوبة 20 ملغ لكل كيلوغرام من وزن الجسم كل اليوم، قد تعطي طفلك الذي يزن 25 كجم قرص واحد من 250 ملغ في الصباح وقرص واحد من 250 ملغ في المساء.</p><ul><li>الجرعة عند الرضع (1 شهر إلى أقل من 6 أشهر):</li></ul><p>شراب ابيتام 100 ملغ/مل للحل عن طريق الفم هو أكثر ملائمة للرضع.&nbsp;</p><p><strong>طريقة الإستخدام:</strong><br />ابتلاع أقراص ابيتام مع كمية كافية من السوائل (مثل كوب من الماء).</p><p><strong>مدة العلاج:</strong></p><ul><li>يستخدم ابيتام كعلاج لمرض مزمن. يجب أن يستمر علاجك بابيتام طالما اخبرك طبيبك بذلك.</li><li>لا تتوقف عن العلاج دون استشارة الطبيب لأن هذا يزيد من التشنجات. إذا قرر الطبيب بوقف العلاج بابيتام، هو/هي سوف يخبرونك عن اعراض الانسحاب التدريجي للابيتام.</li></ul><p><strong>الجرعة الزائدة ابيتام&reg;</strong><br />الآثار الجانبية المحتملة لجرعة زائدة من ابيتام هي النعاس، والتهيج، والعدوانية، وانخفاض الوعي، وتثبيط التنفس والغيبوبة. اتصل بطبيبك إذا أخذت الأقراص أكثر مما يجب. طبيبك سوف يتعامل بأفضل ما بالإمكان لمعالجة زيادة الجرعة.</p><p><strong>نسيان تناول جرعة ابيتام&reg;</strong><br />اتصل بطبيبك إذا كنت قد نسيت جرعة واحدة أو أكثرمن جرعه.</p><p>لا تأخذ جرعة مضاعفة لتعويض عن جرعتك المنسية.&nbsp;</p><p><strong>التوقف عن تناول ابيتام&reg;</strong><br />إذا توقفت عن العلاج، كما هو الحال مع الأدوية المضادة للصرع أخرى، ينبغي وقف ابيتام تدريجيا لتجنب أي زيادة للتشنجات.</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء يسبب آثارا جانبية، على الرغم من عدم حدوثها للجميع.</p><p>بعض الآثار الجانبية مثل النعاس والتعب والدوخة قد تكون أكثر شيوعا في بداية العلاج أو عند زيادة الجرعة. ولكن ينبغي لهذه الآثار أن تقل على مر الزمن.</p><p><strong>الآثار الجانبية الشائعة جداً&nbsp;(قد يؤثر على أكثر من 1 من كل 10 شخصا):</strong></p><ul><li dir="rtl">التهاب البلعوم الأنفي؛</li><li dir="rtl">النعاس والصداع.</li></ul><p><strong>الآثار الجانبية الشائعة (قد يؤثر على ما يصل إلى 1-10 من المستخدمين من اصل 100):</strong></p><ul><li>أنوركسيا (فقدان الشهية)؛</li><li>الاكتئاب أو العداوة أو العدوانية، والقلق، والأرق، و العصبية أو التهيج؛</li><li>التشنج، واضطراب التوازن، والدوخة (الإحساس بعدم الثبات)، والخمول، ورعاش (رجفان لاإرادي)؛</li><li>الدوار (الإحساس بالدوار)؛</li><li>السعال؛</li><li>ألم في البطن، والإسهال، وعسر الهضم، والتقيؤ، و الغثيان؛</li><li>طفح جلدي؛</li><li>الوهن/التعب.</li></ul><p><strong>الآثار الجانبية غير شائعة (قد يؤثر على ما يصل إلى 1-10&nbsp;من المستخدمين من اصل 1000):</strong></p><ul><li>انخفاض عدد الصفائح الدموية، انخفض عدد خلايا الدم البيضاء؛</li><li>انخفاض الوزن، وزيادة الوزن؛</li><li>محاولة الانتحار والتفكير في الانتحار، واضطرابات نفسية، السلوك الشاذ، هلوسة، والغضب، والارتباك والذعر الهجوم، وتقلب عدم الاستقرار العاطفي/المزاج، والتهيج؛</li><li>فقدان الذاكرة، ضعف الذاكرة (النسيان)، تنسيق شاذ/ترنح (ضعف تنسيق الحركات)، تخدر (وخز)، اضطراب في الانتباه (فقدان التركيز)؛</li><li>شفع (الرؤية المزدوجة)، عدم وضوح الرؤية؛</li><li>نتائج غير طبيعية لإختبارات وظائف الكبد؛</li><li>فقدان الشعر، الأكزيما، حكة؛</li><li>ضعف العضلات، وألم عضلي (ألم في العضلات)؛</li><li>الإصابة.</li></ul><p><strong>آثار جانبية نادرة (قد يؤثر على ما يصل إلى 1-10&nbsp;من المستخدمين من اصل 10000):</strong></p><ul><li>العدوى؛</li><li>انخفاض عدد جميع أنواع الخلايا في الدم؛</li><li>تفاعلات فرط الحساسية الشديدة (متلازمة دريس)؛</li><li>انخفاض تركيز الصوديوم في الدم؛</li><li>الانتحار، اضطرابات الشخصية (المشكلات السلوكية)، التفكير الشاذ (التفكير البطيء، غير قادر على التركيز)؛</li><li>تشنجات عضلية لا يمكن السيطرة عليها تؤثر على الرأس والجذع و أطرافه، وصعوبة في السيطرة على الحركات، فرط الحراك (فرط النشاط)؛</li><li>التهاب البنكرياس؛</li><li>الفشل الكبدي والتهاب الكبد؛</li><li>طفح جلدي، والتي قد تشكل بثور ويبدو وكأنها اهداف صغيرة (بقع السوداء مركزية تحيط بها بقع باهتة، مع وجود حلقة داكنة حول الحافة)&nbsp;(حمامي عديدة الأشكال(، طفح جلدي على نطاق واسع مع ظهور بثور وتقشير الجلد، وخاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)، ومن أكثر الأشكال شدة مما تسبب في تقشير الجلد في أكثر من 30٪ من سطح الجسم (انحلال البشرة السمي).</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحفظ بعيداً عن مرأى ومتناول الأطفال.<br />تخزن في أقل من 30 درجة مئوية.<br />تاريخ الانتهاء يشير إلى اليوم الأخير .&quot;EXP&quot; بعد تاريخ انتهاء الصلاحية الموجود على الكرتون بعد كلمة لا تستخدم ابيتام&reg; من ذلك الشهر.<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية رمي بعيدا الأدوية التي لم تعد تستخدم. وسوف تساعد هذه التدابير حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>وتسمى المادة الفعالة ليفيتيراسيتام.</p><p>حبة واحدة من ابيتام 250 ملغ يحتوي على 250 ملغ من ليفيتيراسيتام.</p><p>حبة واحدة من ابيتام 500 ملغ يحتوي على 500 ملغ من ليفيتيراسيتام.</p><p>حبة واحدة من 750 ملغ ابيتام يحتوي 750 ملغ من ليفيتيراسيتام.<br /><br />المكونات الأخرى هي:<br />القرص الأساسي: كروسكارمللوز الصوديوم، بوفيدون ك- 30، الجريزوفولفين السيلولوز، ستيرات المغنيسيوم .</p><p>الغلاف: اوبادري أبيض وملونات.</p><p>* الملونات هي:<br />قرص 500 ملغ: أكسيد الحديد الأصفر&nbsp; (E172)<br />قرص 750&nbsp;ملغ: أكسيد الحديد الأصفر، أكسيد الحديد الأحمر (E172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">اقراص ابيتام مغلفة بغلاف قصديري من PVC/PVDC&nbsp;</p><p style="text-align:right">اقراص ابيتام 250 ملغ المغلفة&nbsp;هي&nbsp;بيضاء اللون بشكل كبسولة، مع خط بالمنتصف مطبوع عليها رمز&nbsp; &quot;JI 175&quot; على جانب واحد.<br /><br />اقراص ابيتام 500 ملغ المغلفة&nbsp;هي صفراء اللون بشكل كبسولة، مع خط بالمنتصف مطبوع عليها رمز&nbsp; &quot;JI 176&quot; على جانب واحد.&nbsp;</p><p style="text-align:right">اقراص ابيتام 750&nbsp;ملغ المغلفة&nbsp;هي وردي فاتحة اللون بشكل كبسولة، مع خط بالمنتصف مطبوع عليها رمز &quot;JI 177&quot; على جانب واحد.&nbsp;</p><p style="text-align:right">حجم العبوة: 30 قرص.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الجزيرة للصناعات الدوائية (JPI)<br />الرياض، المملكة العربية السعودية، الرياض 11666، صندوق البريد 106229<br />رقم الهاتف: 8172-207-11-966+<br />فاكس: 8097-207-11-966+<br />البريد الإلكتروني: medical@jpi.com.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة الأخيرة بتاريخ 2015/10 ورقم النسخة 1.0
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epitam 250 mg film-coated tablets.
Epitam 500 mg film-coated tablets.
Epitam 750 mg film-coated tablets.
Epitam 100 mg/ml, oral solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets:
Each film-coated tablet contains 250 mg levetiracetam, 500 mg levetiracetam, 750 mg levetiracetam .

Oral solution:
Each ml contains 100 mg levetiracetam.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet:
Epitam 250 mg film-coated tablets are white, capsule shape, scored and debossed with the code“JI 175” on one side.
Epitam 500 mg film-coated tablets are yellow, capsule shape, scored and debossed with the code“JI 176” on one side.
Epitam 750 mg film-coated tablets are light pink, capsule shape, scored and debossed with the code“JI 177” on one side.

Oral solution:
Clear liquid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epitam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.</p><p>Epitam is indicated as adjunctive therapy</p><ul><li>In the treatment of partial onset seizures with or without secondary generalisation in adults adolescents, and children from 1 month of age with epilepsy.</li><li>In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</li><li>In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.</li></ul><p>Epitam concentrate is an alternative for patients (adults and children from 4 years of age) when oral administration is temporarily not feasible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br /><em>Monotherapy for adults and adolescents from 16 years of age</em><br />The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.</p><p><em>Add-on therapy for adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more</em><br />The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.</p><p>Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.</p><p><u>Duration of treatment</u><br />There is no experience with administration of intravenous levetiracetam for longer period than 4 days.</p><p><u>Special populations</u><br /><em>Elderly (65 years and older)</em><br />Adjustment of the dose is recommended in elderly patients with compromised renal function (see &ldquo;Renal impairment&rdquo; below).</p><p><em>Renal impairment</em><br />The daily dose must be individualised according to renal function.</p><p>For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:&nbsp;</p><p><img alt="" width="444" height="158" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAbwAAACeCAYAAABJo79WAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAACSRSURBVHhe7Z1diyvJecdzM18mX2BBlwu517VhQTcLRhAQhgUjMAjDQAgETGBgsbCRLxZCRGAuohAijD0GOReKDyKH4WyO8NkxZgQb7yraHWRz0Nmp1FNVT/dT1VWtt9Y5OtP/39CMuqvrtauef1d1dfVfKQAAAKAGQPAAAADUAggeAACAWgDBAwAAUAsgeAAAAGoBBA8AAEAtgOABAACoBRA8AAAAtQCCBwAAoBZA8AAAANQCCB4AAIBaAMEDAABQCyB4AAAAagEEDwAAQC2A4IGD2Txu1LhzoS4u7NYZr5zL+8tm1lcX/ZnbezvM+h01Xm3cnqXbathy7YzVauO7nZpR96qQnpDNZqb6On392WFp641GB4URKysAdgWCBw6GBS8UusfHB2PIygRwNe4UhGXWZ/F8N0bNiN07EJjVZmXKMTT8pozOUPBYqOhaHSJ4VM7d0eSgMFJlBcAuQPDAwaQE7+6/fq1ajZTgvVFTfXdvejBC8L78jfYzuTe/HzdLNWg21WC+Nvtvg/tJS10O5jpPj+7I24VuEqbty6wMiHcleLtQ1juj6zfqttQw4sblTKV8aC8xVlYA7AIEDxxMSvBSx4lbfWc/0wY87OGNukNznGFjnxKgdtP1BgNBML0013OwW9/Gp3sGJMKx3qPtkdrzCO5FyN4H9z4pT/5Qrh+eny7RE2q3s7TmPdkL1e5NnU+d9tVYdWQ6AsEL05WFI8pRnmPyrsNs8G8dTlY+2k8qH5QHKULxMmWxcvE1WiadsvdHW3c0d6HocIxbnj8peHm6G1k6ivE2c79BWQGwCxA8cDAHCd6tNfCh4PUGw8ywE8bYJQSPjN1AC4U1ermh5v3l5tETC2tMxfHAUD4+LDxhIcgYX7a6bs/u9116b0fXWZwyvFi62Ki3exO1on1yE/meTXPBY6PPYhMKHtPWvV8Tny6jWBlLISGmvUGWXmLWt+lN5WPaa2d+wzLuXl2Z9HAcLJRyGDSMn+FryvkJz6M0LB7s9Q7jJTcpnmFZAbALEDxwMPsKHhmxxTI3YIcKHhMaTGsk++pB++HfLEQdY5x5yw0psVnOo8Ii07Qa9zM/NFzn9zyC8ES6+LdvyOM3A2zE2S0leLejro1XlF+ILF9zvvtN8fdd+Kl8FAUvv0HgnnhY9p6fwI0J85Of5+ebCOOlfbqZYMKyAmAXIHjgYPYVPDmUl2/WqPXauXEj2GAbMRLnsxHNjL44xkaQxEX2Jth4khDGSAkexUF5MIZZuIfDr5IwXaHgESZt7hx5fFfB40lBZYJn82wFbD7LxWM1HmdpT+VDilfYk+KbgCoFz5aFf9MQxktlFuvhQfDAPkDwwMHsK3gS2QMhisNuaf9kzK+68WntuZj4vQPqVUlxkcSGNAlzXIcz1mmVcVDPKDTmRCxd/DsWN5WBfIYXGvmU4JnnoC5PZWVsy3CmlssH91v37kSZp/IhxYuQAs3pDct+F8GTNyFmX5zHeZU9ehkvXQd5wxKWFQC7AMEDB1Ol4JleltvnHlmqF0V+6W4/NKxmPzCaBBvHzFjrHo8UV9tj8nsYBOcjFB3bixOC6sKLpYt/s+BR3nhIkdxGQvDsuXm4McEzebkemd8sCCmjz+4Ut/3t5zGVj4J4BWkgZB6JnQTPHM/TEJ5Hosy9uFS8jPWbriMAxIDggYNJCdu3X7xUNzc3dls8uKM+JHCh28PC+bmZmwkmKUignrvz5nPrZ77cqPXmTg1bbRfGjerpHkynNTE9g9yP3iJpMtPl29PCsOf9qB95PeKNWnBYIrxYunh79uKVPWezVHNx/PUbc9iU5Xyw/bUEKiMKi85fijhiPUhzzmJpXgGgtC3mS31MnlfMB/l58Yz27TUIy/QXP7/SZTrUQt3Lji0e8rLldPC1fPnFt2af4XJ+/d2fvXJYPOT5iV1L2n74t/9on89GygqAXYDggYMhw7OtJ/c24SEzNuphL3Ib7J8FhsSJe2OnJDU8FxO8t01YJrInfigUpnweFyOMl+gOB8myAmAXIHjgYFjw+DnLOQifnBhzSHrMcKo26EZs3Ltlp4bSHBrwd7m0WIgs04Z4VeMYRpOJ+5VGxksb9fxiZQXArkDwAAAA1AIIHgAAgFoAwQMAAFALTiZ4+Yy7G/Xi1dd6f2FmWMnjN89furMr4M1r81Jsd7rrzK03Zip186L4TOCre5vWXdnlcyrE3fRaja970Rl1AIDz5dl//24P22LZZ9Yxz5al55QSehe0LAyaRDQYds057WbjSc1c/d0vP63cVlYuePxujXzYbt/3Ee/fuJdmq8zM6Hr/h/vhe0DM/K58Btkx2Djtuo4AgPOH7NX1llmlIbu+V8qzTmmCFc0KJrvI9si49dPL6/Gksac6iYduBGLvxx5DpYKXzdqLzCyTaxGeRPBGPfdrd1KCdzc/neARNOU69X4aAOC8oJmh+9qqXVcOkjYoFDCyE2ViZgXh6QoeYV5POfI1GEmlgsd3KNumg28TPLqzsZ9ysWFlvUa6uOIzKwy584oV3rkzF445395JmSnOep/ummKCR+fN534Y7K87uvXC4DTw51TScfsVkvIvF8IlwinY+VbtHQ4AYHdsm7bLmnk2RG/U5s3noCIGeZ/PXdm231f367n/JQ1nE+Tyc5Jeu5mlRa6YI9dzpbR5dimwn3memtlydTI8E4dLk5f/Ztsc29XeUnz+a0zWrpF/+1ipeL4Jv6R3fAjVCp5Ze9BWhDLKBI8LisayjbqLgqGC5c+sSOg8+SJrfhE6ar7Slcj9NuGIuPk8mV5yXwo36a/hvtXFYbC/2LJKedxFwaI8Dgf790gBAG8XY4MCoWKBIiOcep9w369/mDDFe59kI9jO0TuZsU5EqodHz/SIzBYJ0YvaT3JrW3tkz8ttFs29YLGhNHI6yOaxEBZtnv0d2sqyz1H55+fxsx6EeTyUaoc0adzaZa4MLoSY4Fm34sr2XKhRkdSFFxM8SkdYKWQ48jyGVpM3yxcFbmbfqxS5W2odwVSFpIt4dVXNC7wAgNMR65mxESZbl3o0sb/g9VUrJWxm5KzYy4nZF7KftIA5k3carF2K2U+CVrEhsrw5MZve3pr/oRDZzo0TqRKbJ912+hxVYFs5PdtGDXelUsH77vU3pkvbHMwLF5YKiAs7JnjU3aV1/9Z3Q9VoXKn1d75/LojYBVtPLisRvPX6Vo3dLKfQzexXKHiDn/7I7Vm82aveVj7DizDrUgo/lLdXL555+/Kc5y+/2NtPuE/bN9987e2fws8haUX+btR8flwc4T4fO7YMZbp2Of+QOLb5efYszwO7pyDbEgoV2ar5aGS/NnEd7+F99snP1GSdt/u7YUM1hnduL4dsxKjZUMM7fe6b12aItDkqzrSc9XOxYaKCp+3nDz/5zO3pfWNrL3VarF1K5fXlf/yTurq9V3PdY10+LNWg2VQDfa3uvvjSuFO4jYumGt3buKwIU7j7CN5l5l+yi+BdTsL1bA+jUsEjWMyokvAdjrkbcHcMREzw6E6KVJwzmK2a7lZw54KIXTByG8q7mh0ugGkEYeHKiTWBm9mvSPDoHLlKPgDgPLHtOZ9Vbe1TLj70jCts3wQJbDbkZ+xd/DkU2zs6l+1F2JuhsKI9v4h9ofBaDftFfIKHIdkupQQvfBzFPUM/39Qrs/mgG3ROU5nNk247f52j4D9edodQueARnOis6+oecBL8IDa2yUzSg0xzXFcEGV5qLT+epRnGbR7S8u9Z7tbUx73z6KFp34o0X7SYP/mb/dkJNtQIyuLOLxhVJszSBOD9gGwWCwXbL745t23fb99Mbutygcxsi+wACJsViggdS9o8OUQoOhhlk1ZSYZkJJc7+mX3yUzKUG5u0QlvK3tI2vb/39jltbOvD802nhIRXlNWxnETw3gVlX6E+J2ylwXt4ALwvUA8tnFUNTo+d1Vkcyj2GJyN4pksu7nLOEb5Dit0NAgDOl3ASCjg91FOt2lY+GcEjzFh5hd3fqqEhDogdAO8fZpLGGduWp8ghi4ls40kJHgAAAJACggcAAKAWQPAAAADUAggeAGfIrp+csu94VTuTrTfK32mtAlq9KJxBze9e8bR2frY9mVQbNwASCB44ith7ldmiAW6BAXu8WqP81HlXgkfvPclVi47FTC0f+5M9+N0r//1Wm/5TzMwDgIHggYOhmWvjwDjRijlm4W/34ipP5bbCWFwjFeSQeIXl+TYx4hm8bHwssTpCpHp49sVs3ByB0wDBA5UhX6rf6Lt3OYzFhi21tFHd4d7wu+zdnOK1mc1yGV0QIiV4RNWrawDAQPBAZaxvr1Tn6lbFJG1zP1LN5kD3HtwBjVkwfH5jFsz96JPP1P2oaZY+Cpddo17CoN/OFvttN/vqf79znxu57plj3VZHtbpTdb+5V//w4Qeq2R6pUa+rutf0v22G0P7nq7UxtHY4zS4hZ/Y/+J4Jp9dtqUajpbo9G+5H32upSWSx26/+ODVfu6B4aS3FRutazdf3LqyPXLxzfQOwztL486u+SR/1cE1+mk3V7lEcXXXLfnW6mm2dn/lSXX3/Az+Nxo3TRX5suu6neX7+9OxX3nk2P1fqKy04sbJ6Y0KwmOvTGKo7I05vCnFy2fz000+z31w2lJ+//8GPXdgN85mbbs/m9fPf/96cQ9xNu6p1aa/jhx/8dVLwaBH3q0a+UDEAVQHBA5XAvbvYUJR1Sy8AS+5mTcLEXT33fuQCumRk8+eDvNn4yVhLAyp7l6GBNfs7LAouSS1jJ8MiON1h+iQcR1ncu7rxOo2h2/SOv1Hmp0Uub8efwfHWUtTnhWFFy1Dnk5fesnnOr/XdXD7PzfOfyjfBKxLJ6w1AFUDwQCWUDUPJr1CkIANYNoxlwjeG2hl3I3hxEZWCQJQaa9rfU/BSy0zJsIjQ+EvYqHN+yuLe1a1c8MpXnD9G8Cgv/EFjc51cOHR8ubS9dXv98jRwHsKwCAgeOBUQPFAJqec/ZOi2GS4ycJProTbK242cMczacN6vba8lFuepBS81g1KGRXAPLwxD9nZShj8lakTKbVsPj4/HkEJl9oM4eT9WhgQN7dobklzUKJ9Lfb75bQRvvx5eWXoBOAQIHjgaa7SKPQhj5ESvjQzZ7dSf8m6NG090IaNYNHRkOPtOCDmuu83a9ZCEgY18X4tgA2pmjwZxmPD2FDzz+RUpDvKbjULwOF6encrnyd5UyvCnRI1IuaUEb3IfLys5pGnPzQUpjJP3UzcNk8irDNSz5zjYD9eHVL4Je6xYnwA4FggeOJpQ2AjbEyMj629kMCX8Ht/1nMXBbp4BdD2l0C0zorzpNNAxmmxB+7K3mKWn38/8lH/nUH6nyze8LCx8LsfLx2S8XhpdGcljjUYj85O/09jRx+3/wjcWvXTJMuuoYTf17cdetKxCuJce5s8PSwuV52ZFi9PEW2c8M99X874UHlzHcMuua6Q+AVAFEDwAgIGei47afTX54zfuyG6s7yfq1y++dHt2tm6jOTronUuaATscjLzeJwBVAcEDAHiMJhP3a3fo1RLuqW17DlvGKT4JAwADwQMAAFALIHgAAABqAQQPAABALYDgAQAAqAUQPAAAALUAggcAAKAWQPAAAADUAggeAACAWgDBAwAAUAsgeAAAAGoBBA8AAEAtgOABAACoBRA8AAAAtQCCBwAAoBZA8AAAANQCCB4AAIBaAMEDAABQC96q4D0+PqjFzY1aPDyNz/c/bpZqfjNXmwqz8+0XL7Pyefvl9aY0vofFjbrR7jc6z8sDMm3y8/ILt7c/76r+HJvvd86b1+pm8eB2TsvD4nRl9Ob1/229Dn4dKa/PoH5UKnib5Tz7zH9h63RUx/3uzzbOR/XM+jLejppMpmq22QTHLyoxAJvVWOepU1kD32xmqqnTxuVD+32xf2qmvbYpm1h8q7G+fuOV+W3Ksj8zv3eF89Js99yR/WD/qfSdimPzfQ70BkO1irQB3jh/DNcDaj/jlfY3Hhv/EnM9OsXjq81KjTunuUbX42vzP3UdwjpSVp9BPalc8LhyWTGwlY3uumzjOJ0BN3FQZReNkBpfq9EwjZaQaTpXqJFWlT7K73iPsLgMw/g3j5tKjJgxSAcKHsEG7W1dv6ry/S6hOnA9mrs9uy/bwGbW90SP2szVVTf7TfmXbYqhGwEWxBB7neJuh0JpGQ621x1ZR1L1GdSXigVvaXpT5nfQsOxd4ukM1u2oG22Ym+WiloJHw6375jVlIKoyHO+b4D0Fg0m9ITmkF7aBUNSojIfdkXEjjHvfb1f2WF/fxMZ7WoQR0gp7w7vWHQgeKONkz/Bi4pJXRtfIGq1iQ6Lj+pyWbnR8vh2WiPthRt1WYWgmZJvgyfgpLD/+mWoGcfMQERsUf8iorx4e/aFO6d4Vd90yXtoofX7c/vCMdEvFPcqGpfTmjFkeT97rJWLxS3rtZh6WDptvasxNBh/Xxo3T1Wxr0aZjwQ2IcWe3wJ17UzK86HG9UV1oNfi39c/5D+uALJd2b+SVaZ7eXlDe+e98s/nOwgvyFtad8BjV5xjtph9eqgxjYXnXXJ+3CeqbDcuvh2Eb4H2ZZjkqEoPEjM4v7eWZcEvaQKItXVw0s/rFcC/UbvY6eHW22XZn6nNd+VH+YoJn8+f86TrmhaPDHmg7IuPhuOkRiFfezr3dLKYXnC/vRPC4kYy6V1ljsRUvbzzd1qWtcCV+JGSUZVwxygSPKz415MeHRRZfHn9f3a3X7mwLu5HomLDFHe1M3wEXDY1rRPr3lTCApiE5vzIfZY13W9z3m3vvfFm+9lmrTQvB8dt8F8sndac8GNqhr6yMdBj0u2mMljaIwXXK3US5unTTxBA2utKNjvM5bHwoHXQDwOcTxo87jymUy3Sahe2Vo+s5ZPGaslmp9dovQ76G9+u5/p/X1XjdiddnCYU36Ok0mXDzcykdsgyjbcOlhetT7FmyKa9ACO25lMd8C68r3Txat7yOMPYGxMXL5RWUO8FlUuxdWr+yHZvjLoyHxaIQJyGvE0F1lq+/uRnkOuLSRHmK1VvyN1/6aS/6ycuaMO2JrrmsS/pYLJ3gvHlHPTx7TA7fFRuivcss8yPpthrR45JYmhjZGCVh/BJ2y0RH/5ZGOIXxx0bW+MsbmFcmIu6tghfEXTjfnZOXr41Txp8Stthx8idF24oRhZPnLUTmm7B+igaQ4PCu2sIwyvIgYRG9rNW47/knYuUiw8j2A8Fjt13Lw8bj151iead7TWVpIraFxf6luBCmB5YQPD/tOkxRloTtvbn4hKE35e4Zfjqn2JNjwSNxiRFr+2Vtx7tO5vy8zcRuUCns+HXKbwzyOqtvKii/JH48ouDySH76Ol38iGCX9g3OlzMTvKYa3efnE2V+JP/8k49Vc0CvCPgNj6ZksyGIpklX8OViqdZ3Q9VoXKnbdXn8Enbj8Knh0bRpEt9me6remKMWajDXvWs1vu6pns7DJ9x4TaO7VBMX7yGCR4Rxr7/7yj8/Vb4i/l0NPLHR5fXDTz5zexw+haPTJYy1xKRZGnKKuzFUd9rQ/vQHP/LSxuF9/PFPsrLxykP/zQdN1WhN1Hw+UP3YtdfIcvnX3/7JC4OQaQrdwnzzNfzZp5/4s2kjdSdV3hIKb/Tpp6Y+FGbnynKKhBXWJ/IfCt56crlV8AhznjtGeX79Oq+5d9OuGQK8nNjRjckvB+7VALt1e9b9X37zpXFnWPD+8M137oif5u9/+IGXBr5OH3/844J4Et51ovIW5UHh2rq3RfCcv69f2/DzOqvP1WEMmg3177+7VcsH+t1Ug/lcTYaTLD1hG4ulE5w3ZyN43ED4jv9RV7rwjo1ICZ6t9Np/cKfaG4leSCRNdGdHd21Z/M5AbGbjaPwSdiNDQ2HTnWB+3L/r5bttSptxD4ws31GmBI/vPPkO0wpVOu74kKYtX0pXmD+Kfx/Bo/Bajfz5BQ8xybyFSDeZN8I+D8x7SRwelUd2tx34kddMXnMmLJdRb5r5keXIr0qE4Yf55mu4TpWtV3fy8pb1WULh0bPcMF6zL8pQXjsOq98P6pP2HwqePe4PdYZtgPc5bPJz2bJD1YR1d70gSsd18VkklWFD+CFs3Ok24NVzcZ2mvVFWBySyTMLyiA2HU9iF6+f8tXU9IOSwKOHVBdO+RC9S25ewjcXSCc6bkwieqdimEdlNNmo+ZiaBZL9dxZfnNNs7+ZGE59PG79vZoZf4Fo2fhjeC8OTwTN7o3ASbzHDYLUyfH1ZH9wiE0Q38sn/2w2F55Uqz5PR/M+EiEXee59yYyfwxqfiZ/JmO3oS4pCat0L40JJJ8AkxuTIjC5BSXvuxGJtjYuJNhSsUV5ov9hOVoe1f+taYwi/nmcxqq49KaXcNI2XrHxMQKhtxtfdY3XVl42vg7PzJfYVjevvMfig5BdYDznW4DufGmcCfDgedOdUHWd1k3vDKWdYoEQ+wTMs2NRsP8pzzKMGLvaXpxuPon08Nl65eJTmc7n7iVtSHtT05akZDb7dROJjNhiboe1kMOD5NW3i9O1sMDx8MNWBoY4IPJA+WQWNDEmLeJFSP/hgaAcwCCd8ZYwYPhSEHGnIeZQBpeaeVtwD0v3KSBcwSCd4bIoScYjjg0cUAOr4I0ZjguGL47FVR3UWfBuQLBAwAAUAsgeAAAAGoBBA8AAEAtgOABAACoBRA8AAAAtQCCBwAAoBZA8AAAANQCCB4AAIBaAMEDAABQCyB4AAAAagEEDwAAQC2A4AEAAKgFEDwAAAC1AIIHAACgFkDwAAAA1AIIHgAAgFoAwQMAAFALIHgAAABqAQQPAKA2s7666M/c3nY2m5nqX1yo/mzjjlhW47GabfxjKTarsepcdNR4tf38Wb+jlptHtwfAYUDwADgTHh8f1OLmRrUvW+rnv/iF6vau1fi6p9rNSzVZb9TD4kb1ui31Nx98qG4WD87XcTxulmo0GKruaK42j7sJCqVz2murZiB46/WtGk/u3d52KO75zXwnIds8btT4Jz+B6IGjgOABcAasNis17lyoi85Y/w57Tf2sF0S9ost2z/yuglm/2EvbhVgPb5/e3SE8Piz26oUCEALBA+AMsMN7F6ozXrkjccoEz/SCSDR1OLRRWCRMtidmBUoKKvXU+hf9TKRYxJrtbh6OOd+Jsd6nnqA8lwXPxD2eZcfp3P5spVqNYhi0T71JElt73qYk7lxAqUfYEekFYF8geACcAeYZmjP+ZZQJ3u2omwmmDc8+H6PhxwsjFCu1Es/LTI8pEBUrkA3jj0WYw5Fxh4JHYjRm8ctEr6Pmq3khDNpfPDwWwijG7T/fY0HfVkYApIDgAXAGrMYdLQrHCd6oO4z2fkjwYuFulvOo4PUTolbqtlwWeorkZnuRQRh6PyV4qfAJFrxtvWAAUkDwADgDqujh9QZDT7yYtyF4t/M785+QbhA8cE5A8AA4A8iYz69bqtFomedkPBeRhh17o5ERCCImeKv5tboa3qrffPp3qnWdz7Z8fFiaWY0pwXt8/bVqNq7U7VqISonolLl9/vK5+U9ItyoF77vHv6hho6lG9/kxAPYBggfAGcGG3kzaoE3MSuRJHrFNikt2XPul8GjSCu3HekZylqaMO5vkEtkvuq3U7dSfzJK5ten5YdGfNznFPKsrC9+mD7M0wbFA8ACoMXZyyPsx8/F2dO1NYgFgXyB4ANQc8/wweJZ3btBrDcOBP5QLwL5A8AAAtqd3xsOFNPTKzzEBOBQIHgAAgFoAwQMAAFALnpTg0SyufRbVpVlttFhvOFTyuNmohx0X0iW+fnW/96K2f/nzn92v8+HrVy/UjVjM92Gx28K+AADwPnAywZNTqFvdkd63M8G8qdXNtjv7eGLLJJUhp3DLd30I+RLtLoy6V3vNHqMH8MulFWaexr3tZdp2U5QbbS6vdn1BPn7cbLu7+dz7TAyvf4hnJwBUz7Ftf9RtVdLu60Tlgpe9hyPEh9b447X0CDsVulpDOrref5YZpzUUvPmdfafoVFD+l/TirSsHqrRllZ7PZ2gZKj5/Oppk+TY3E0dOPDBlIsKg/aG+YQEAVMexbZ/a5cQt5F1Fu68LlQoeL/0T62mFnzipXPBG+09ZTgke9XROCX1GhYdMuRe17S6PsefnNw/r9dr8J2Tv7FDo2vSDtNBKHwCAajmm7W9WWvScDami3deFSgWPh9e2XcBtgkcX1nxWxIXFwkT7ZuWGQFDJfdSbZr+zc7d8niQmeHTefO6Hwf66o1svDE4DDTlQGOm4/fDpMyoMp2vXSm/KLgiTsGXqD22E6dmWD2KmxTgMO1yU2BuW9jZ/dXsA6oS0Mc12L28nCTGqou3H2j1IU63g0XM0fYHDHlNImeBxJZgvtYCYBXXdHY0z3u3exPvECUHn8Xe6iNzQ7/d5EoLczXCjCIP9NYLPprA/uVZhMW5fBMgvf0aF2LfSy+FMJhegYsXfJx+0mHDs2tGQdOw4AKAItce2vgEnu1TWro9t+/QF/FS7B3EqFbzvvvmDuQDbjCMb2pjgbe6GqtEYqr8EsyTZcEdFUleEmOBROvZavPZxo27HE/VGnOf5SyxsGxM82i/E7cKXM0D3qfTr+4lqXQ6iMyfN4sOjtmpeXKpJuBjwjvl4+fxG3dzQtvDSKL+zRlBDs+eF2/6zOklk2b+5JmKftm+++drbD8+pws/zl18UwqBzXr145u1vi/cQP+eav/m8eH7VcYT7tIV5k+k4VRyH+klBbfHqow+2DjNW0fZT7R7EeWvP8OhuJzO6EcEzF7+v/Rm3TvHCOuMcq2ipHl5UdEQ4ocGXva+CG+0fK3gifGafSk93jhxWDBt3fFjTS1/JivQx0MMDYHeoTU+uh8bGlbXrqtp+rN2DOJUKHsFiJkUvXOU8Kniuu86VgAVsM9MiQcNvzjhHBU+7yZmE0pDvI3jexJrAzewfKXgyfGbXSm/DKq/UVIbhXeU++Ugx7Y3QmADYAdue7Q27fSSTbl9Vtf1YuwdxKhc8gg2pHV/Wm3jfLn/eVNykUeZPmtCFlOE1Wl1zTgjP0gzjTn+eRIuU+23ddOWjHqauVCxUMX+xT6PYCTb0jKws7jx8plBOrtJmx0UlTn0apdduZv7DhlMoi9J8pAUNszQB2A22b9dzK2ap9nVs22cxpW2XHiKwnETw3gXhTEJQDeYu9BqCBwB4/3kygrfvSitgOzzkEhtGBgCA940nI3gEvQc432MtTVAOzcaE2AEAngpPSvAAAACAFBA8AAAAtQCCBwAAoBZA8AAAW+Hp8qn3YPndzlNgpuBHXslJwe/50mfJiFnfX94P1BcIHgBnQOr91Ni7lfYdVWvEY4t9GwGqcMZy9m6Y3t624Bmx2zMvXCb8/ijPNt62wAJ4+kDwADgTuGeSLcDgXi5m0WPDTQur8++YGJiVN4JFy4+FRe8Us3ZjS+4RpjyOEO7pNO8V2vSjp1d3IHgAnAmh4K3Xt+qqcaEaV7eKPme13typYaOh/m36R+NOa9cuF0vjxtAiw1fDiZpcNdRFM77QOOMvFv6gFm5h5G9fv85+s8Cx4P3nr35r/cxtvLQqEZ1LCzszJl1z6//Fq6/dUf/4sxevjN9pt6UaOlz6nA6Fyaklt1GzqUb3tixo/7lJTx6GTcNGvXiWp0dy+/nn7pfFLEzfHJnF4UE9geABcCaw4MkhzcKSVPocEojop6DM4u32eDYMmXj2ReHwO6uzvu+HRI5/Z71Nt28+exOEbfbdkKbteeY9qW7r0oTNPVLurfbal+acMB4mNpRJa9bKz1zZsso/ASbDoF5u2BvlNJyilwreDyB4AJwJYQ8vM+qB4adP12SiWLLmon0u2Pc+9cSYsIN1aVl8ygQv6/GZ4VYhlLwgeSZEvMlvL0ZEOiF4Zlg2Inhhemif175lt/x5aNOLTw4Jg3oCwQPgTAgFj7DP44qCQLBhZzf6jFMuNPmWMvC88Dj7l6IWCpF0M/ulghcRtsTkkzAe5hjBSwHBAxA8AM6EmODxxBU6Zoy86MGFw4SjycT8Z9idhiFTWEHdfUjTEzwnSMYt6OGF4mOPFyeNhPEwMYGsSvA4D6B+QPAAOBNCseD9UJC4hyJFxBjzyFctSDhin9Qivwsdjg3Thi97QFJozfku7qQYes/w8jQ/Pizz9NFxJ2J8PAyLscd9gTxW8Kyf+BAvqAcQPADOAFqo28w8LGw0g9IaaDLsi8WDevXiWeZuBEjMfpS9F7OYOocTLKpObs9EGAw9H7TnLwozNekZoXG7mXuzP6XgESadzu/N85fuaPp4nveFN4PyftJSl+2pyT/5pVmaNj0iHNp/+TL/LfIioTKaDy5Va3LvjoA6AsEDABwFCd7QrWpSNbGhzX3h3uW2HiB4+kDwAAAHIVeHSfWsqsAM3SZer9gFSifEDhAQPAAAALUAggcAAKAWQPAAAADUAggeAACAWgDBAwAAUAsgeAAAAGoBBA8AAEAtgOABAACoBRA8AAAAtQCCBwAAoBZA8AAAANQCCB4AAIAaoNT/A9IaPWWNPe3EAAAAAElFTkSuQmCC" />&nbsp;</p><p>Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Group</p></td><td><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td><p>Dose and frequency</p></td></tr><tr><td><p>Normal</p></td><td><p>&gt; 80</p></td><td><p>500 to 1,500 mg twice daily</p></td></tr><tr><td><p>Mild</p></td><td><p>50-79</p></td><td><p>500 to 1,000 mg twice daily</p></td></tr><tr><td><p>Moderate</p></td><td><p>30-49</p></td><td><p>250 to 750 mg twice daily</p></td></tr><tr><td><p>Severe</p></td><td><p>&lt;30</p></td><td><p>250 to 500 mg twice daily</p></td></tr><tr><td><p>End-stage renal disease patients undergoing dialysis<sup>(1)</sup></p><p>&nbsp;</p></td><td><p>-</p></td><td><p>500 to 1,000 mg once daily<sup>(2)</sup></p></td></tr></tbody></table><p><sup>(1)</sup> A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(2)</sup> Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.</p><p>The CLcr in ml/min/1.73 m<sup>2</sup> may be estimated from serum creatinine (mg/dl) determination using, for young adolescents and children using the following formula (Schwartz formula):&nbsp;</p><p><img alt="" width="331" height="73" src="data:image/png;base64,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" />&nbsp;</p><p>ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male</p><p>Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function:&nbsp;&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Group</p></td><td rowspan="2"><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td colspan="2"><p>Dose and frequency <sup>(1)</sup></p><p>&nbsp;</p></td></tr><tr><td><p>Infants 1 to less than 6 months</p></td><td><p>Infants 6 to 23 months, children and adolescents weighing less than 50 kg</p></td></tr><tr><td><p>Normal</p></td><td><p>&gt; 80</p></td><td><p>7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily</p></td><td><p>10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily</p></td></tr><tr><td><p>Mild</p></td><td><p>50-79</p></td><td><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily</p></td><td><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily</p></td></tr><tr><td><p>Moderate</p></td><td><p>30-49</p></td><td><p>3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily</p></td><td><p>5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily</p></td></tr><tr><td><p>Severe</p></td><td><p>&lt;30</p></td><td><p>3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily</p></td><td><p>5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily</p></td></tr><tr><td><p>End-stage renal disease patients undergoing dialysis<sup>(1)</sup></p><p>&nbsp;</p></td><td><p>-</p></td><td><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily(2)(4)</p></td><td><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily(3)(5)</p></td></tr></tbody></table><p><sup>(1)</sup> Epitam oral solution should be used for doses under 250 mg and for patients unable to swallow tablets.<br /><sup>(2)</sup> A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.<br /><sup>(3)</sup> A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.<br /><sup>(4)</sup> Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.<br /><sup>(5)</sup> Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.&nbsp;</p><p><em>Hepatic impairment</em><br />No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m<sup>2</sup>.</p><p><u>Paediatric population</u><br />The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.</p><p>The tablet formulation is not adapted for use in infants and children under the age of 6 years. Epitam oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases Epitam oral solution should be used.</p><p>The safety and efficacy of Epitam concentrate for solution for infusion in infants and children less than 4 years have not been established.</p><p><em>Monotherapy</em><br />The safety and efficacy of Epitam in children and adolescents below 16 years as monotherapy treatment have not been established.<br />There are no data available.</p><p><em>Add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg</em><br />Epitam oral solution is the preferred formulation for use in infants and children under the age of 6 years.</p><p>The initial therapeutic dose is 10 mg/kg twice daily.</p><p>Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.</p><p>Dose in children 50 kg or greater is the same as in adults.</p><p>Dose recommendations for infants from 6 months of age, children and adolescents:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Weight</p></td><td><p>Starting dose: 10 mg/kg twice daily</p></td><td><p>Maximum dose: 30 mg/Kg twice daily</p></td></tr><tr><td><p>6 Kg<sup>(1) </sup></p></td><td><p>60 mg (0.6 ml) twice daily</p></td><td><p>180 mg (1.8 ml) twice daily</p></td></tr><tr><td><p>10 Kg<sup>(1)</sup></p></td><td><p>100 mg (1 ml) twice daily</p></td><td><p>300 mg (3 ml) twice daily</p></td></tr><tr><td><p>15 Kg<sup>(1)</sup></p></td><td><p>150 mg (1.5 ml) twice daily</p></td><td><p>450 mg (4.5 ml) twice daily</p></td></tr><tr><td><p>20 Kg<sup>(1)</sup></p></td><td><p>200 mg (2 ml) twice daily</p></td><td><p>600 mg (6 ml) twice daily</p></td></tr><tr><td><p>25 Kg</p></td><td><p>250 mg twice daily</p></td><td><p>750 mg twice daily</p></td></tr><tr><td><p>From 50 Kg<sup>(2)</sup></p></td><td><p>500 mg twice daily</p></td><td><p>1,500 mg twice daily</p></td></tr></tbody></table><p><sup>(1)</sup> Children 25 kg or less should preferably start the treatment with Epitam 100 mg/ml oral solution.</p><p><sup>(2)</sup> Dose in children and adolescents 50 kg or more is the same as in adults.</p><p><em>Add-on therapy for infants aged from 1 month to less than 6 month.</em><br />The oral solution is the formulation to use in infants.</p><p>The initial therapeutic dose is 7 mg/kg twice daily.</p><p>Depending upon the clinical response and tolerability, the dose can be increased up to 21 mg/kg twice daily. Dose changes should not exceed increases or decreases of 7 mg/kg twice daily every two weeks. The lowest effective dose should be used.</p><p>Infants should start the treatment with Epitam 100 mg/ml oral solution.</p><p>Dose recommendations for infants aged from 1 month to less than 6 months:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Weight</p></td><td><p>Starting dose: 7 mg/kg twice daily</p></td><td><p>Maximum dose: 21 mg/Kg twice daily</p></td></tr><tr><td><p>4 Kg</p></td><td><p>28 mg (0.3 ml) twice daily</p></td><td><p>84 mg (0.85 ml) twice daily</p></td></tr><tr><td><p>5 Kg</p></td><td><p>35 mg (0.35 ml) twice daily</p></td><td><p>105 mg (1.05 ml) twice daily</p></td></tr><tr><td><p>7 Kg</p></td><td><p>49 mg (0.5 ml) twice daily</p></td><td><p>147 mg (1.5 ml) twice daily</p></td></tr></tbody></table><p>- A 150 ml bottle with a 5 ml oral syringe , graduated every 0.1 ml (corresponding to 10 mg)&nbsp;</p><p><u>Method of administration - tablets</u><br />The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses.</p><p><u>Method of administration</u><br />The oral solution may be diluted in a glass of water or baby&#39;s bottle and may be taken with or without food. A graduated oral syringe, an adaptor for the syringe and instructions for use in the package leaflet are provided with Epitam.</p><p>The daily dose is administered in two equally divided doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or other pyrrolidine derivatives or to any of the excipients listed in section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Discontinuation</u><br />In accordance with current clinical practice, if Epitam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).</p><p><u>Renal insufficiency</u><br />The administration of Epitam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).</p><p><u>Suicide</u><br />Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.</p><p>Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.</p><p><u>Paediatric population</u><br />The tablet formulation is not adapted for use in infants and children under the age of 6 years.</p><p>Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.</p><p>The safety and efficacy of levetiracetam has not been thoroughly assessed in infants with epilepsy aged less than 1 year. Only 35 infants aged less than 1 year with partial onset seizures have been exposed in clinical studies of which only 13 were aged &lt; 6 months.</p><p><u>Excipients - tablets</u><br />Epitam 750 mg film-coated tablets contain E110 colouring agent which may cause allergic reactions.</p><p><u>Excipients &ndash; oral solution</u><br />Epitam 100 mg/ml oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).</p><p>It also includes maltitol liquid; patients with rare hereditary problems of fructose intolerance should not take this medicinal product.</p><p><u>Excipients &ndash; solution for infusion</u><br />This medicinal product contains 2.5 mmol (or 57 mg) sodium per maximum single dose(0.8 mmol(or 19 mg )per vial). To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antiepileptic medicinal products</u><br />Pre-marketing data from clinical studies conducted in adults indicate that Epitam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Epitam.</p><p>As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.</p><p><u>Probenecid</u><br />Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted medicinal products, e.g. NSAIDs, sulfonamides and methotrexate, is unknown.</p><p><u>Oral contraceptives and other pharmacokinetics interactions</u><br />Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.</p><p><u>Antacids</u><br />No data on the influence of antacids on the absorption of levetiracetam are available.</p><p><u>Food and alcohol</u><br />The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.</p><p>No data on the interaction of levetiracetam with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy: pregnancy category: C</u></p><p>There are no adequate data available from the use of levetiracetam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for human is unknown.</p><p>Epitam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary.</p><p>As with other antiepileptic medicinal products, physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.</p><p>Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.</p><p><u>Breastfeeding</u><br />Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.</p><p>However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.</p><p><u>Fertility</u><br />No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />The adverse event profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.</p><p><u>Tabulated list of adverse reactions</u><br />Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. The frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>MedDRA SOC</p></td><td colspan="4"><p>Frequency category</p></td></tr><tr><td><p>Very common</p></td><td><p>Common</p></td><td><p>Uncommon</p></td><td><p>Rare</p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Nasopharyngitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Infection</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Thrombocytopenia, leukopenia</p></td><td><p>Pancytopenia, neutropenia, agranulocytosis</p><p>&nbsp;</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>&nbsp;</p></td><td><p>Anorexia</p></td><td><p>Weight decreased, weight increase</p><p>&nbsp;</p></td><td><p>Hyponatraemia</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>&nbsp;</p></td><td><p>Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability</p></td><td><p>Suicide attempt, suicidal ideation psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack affect lability/mood swings, agitation</p><p>&nbsp;</p></td><td><p>Completed suicide, personality disorder, thinking abnormal</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Somnolence, headache</p></td><td><p>Convulsion, balance disorder, dizziness, lethargy, tremor</p></td><td><p>Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia,</p><p>disturbance in attention</p></td><td><p>Choreoathetosis, dyskinesia, hyperkinesia</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Diplopia, vision blurred</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>&nbsp;</p></td><td><p>Vertigo</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Cough</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea</p></td><td><p>&nbsp;</p></td><td><p>Pancreatitis</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Liver function test abnormal</p></td><td><p>Hepatic failure, hepatitis</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>Rash</p></td><td><p>Alopecia, eczema, pruritus,</p></td><td><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome), erythema multiforme</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Muscular weakness, myalgia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td><td><p>Asthenia/fatigue</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Injury, poisoning and procedural complications</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Injury</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u><br />The risk of anorexia is higher when topiramate is coadministered with levetiracetam.</p><p>In several cases of alopecia, recovery was observed when levetiracetam was discontinued.</p><p>Bone marrow suppression was identified in some of the cases of pancytopenia.</p><p><u>Paediatric population</u><br />In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. Sixty (60) of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.</p><p>The adverse event profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.</p><p>A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of Epitam in children 4 to 16 years of age with partial onset seizures. It was concluded that Epitam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in Epitam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL &ndash; Achenbach Child Behavior Checklist). However subjects, who took Epitam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.</p><p><u>Reporting of suspected adverse reactions</u></p><ul><li>Saudi Arabia:</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><ul><li>Other GCC States: Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u><br />Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Epitam overdoses.</p><p><u>Management of overdose</u><br />After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.</p><p>The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of &alpha;-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.</p><p><u>Mechanism of action</u><br />The mechanism of action of levetiracetam still remains to be fully elucidated but appears to be different from the mechanisms of current antiepileptic medicinal products. <em>In vitro</em> and <em>in vivo</em> experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.<br />&nbsp;</p><p><em>In vitro</em> studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and &beta;-carbolines. Furthermore, levetiracetam has been shown in <em>in vitro</em> studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.</p><p><u>Pharmacodynamic effects</u><br />Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.</p><p>In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.</p><p><u>Clinical efficacy and safety</u><br /><em>Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.</em></p><p>In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6% for patients on placebo.</p><p><em>Paediatric population</em><br />In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).</p><p>44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.</p><p>In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study. The total daily dose was administered b.i.d.</p><p>The primary measure of effectiveness was the responder rate (percent of patients with &ge; 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods. 43.6% of the levetiracetam treated patients and 19.6% of the patients on placebo were considered as responders. The results are consistent across age group. With continued long-term treatment, 8.6% of the patients were seizure-free for at least 6 months and 7.8% were seizure-free for at least 1 year.</p><p><em>Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.</em></p><p>Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 &ndash; 1200 mg/day or levetiracetam 1000 &ndash; 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.</p><p>Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).</p><p>In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).</p><p><em>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</em></p><p>Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.</p><p>In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.</p><p>58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.</p><p><em>Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.</em></p><p>Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.</p><p>72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. The time independent pharmacokinetic profile of levetiracetam was also confirmed following 1500 mg intravenous infusion for 4 days with b.i.d dosing.</p><p>There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore there is no need for plasma level monitoring of levetiracetam.</p><p>A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).</p><p>The pharmacokinetic profile has been characterized following oral administration. A single dose of 1500 mg levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1500 mg levetiracetam oral intake, given as three 500 mg tablets.<br />The intravenous administration of doses up to 4000 mg diluted in 100 ml of 0.9% sodium chloride infused over 15 minutes and doses up to 2500 mg diluted in 100 ml of 0.9% sodium chloride infused over 5 minutes was evaluated. The pharmacokinetic and safety profiles did not identify any safety concerns.</p><p><u>Adults and adolescents</u><br /><em>Absorption</em><br />Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100%.</p><p>Peak plasma concentrations (C<sub>max</sub>) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.</p><p>Peak concentrations (C<sub>max</sub>) are typically 31 and 43 &mu;g/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.</p><p>The extent of absorption is dose-independent and is not altered by food.</p><p><em>Distribution</em><br />No tissue distribution data are available in humans.</p><p>Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10%). The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.</p><p>Peak plasma concentration (C<sub>max</sub>) observed in 17 subjects following a single intravenous dose of 1500 mg infused over 15 minutes was 51 &plusmn; 19 &mu;g/mL (arithmetic average &plusmn; standard deviation).</p><p><em>Biotransformation</em><br />Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose).</p><p>Other unidentified components accounted only for 0.6% of the dose.</p><p>No enantiomeric interconversion was evidenced <em>in vivo</em> for either levetiracetam or its primary metabolite.</p><p><em>In vitro,</em> levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the <em>in vitro</em> glucuronidation of valproic acid.</p><p>In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The <em>in vitro</em> data and <em>in vivo</em> interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected <em>in vivo</em>. Therefore, the interaction of Epitam with other substances, or vice versa, is unlikely.</p><p><em>Elimination</em><br />The plasma half-life in adults was 7&plusmn;1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.</p><p>The major route of excretion was via urine, accounting for a mean 95% of the dose (approximately 93% of the dose was excreted within 48 hours). Excretion via faeces accounted for only 0.3% of the dose.</p><p>The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.</p><p>The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.</p><p><u>Elderly</u><br />In the elderly, the half-life is increased by about 40% (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).<br />Renal impairment</p><p>The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Epitam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).<br />In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.</p><p>The fractional removal of levetiracetam was 51% during a typical 4-hour dialysis session.</p><p><u>Hepatic impairment</u><br />In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).</p><p><u>Paediatric population</u><br /><em>Children (4 to 12 years)</em><br />Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults.</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.</p><p><em>Infants and children (1 month to 4 years)</em><br />Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).</p><p>In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. Age also had an influence on both parameters. This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.</p><p>In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity.<br />Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.</p><p>No adverse effects on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (x 6 the MRHD on a mg/m<sup>2</sup> or exposure basis) in parents and F1 generation.</p><p>Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m<sup>2</sup> basis) and 1200 mg/kg/day for foetuses.</p><p>Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. The NOAEL was &lt;200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m<sup>2</sup> basis).</p><p>A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day. The NOAEL was &ge; 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning.(x 6 the MRHD on a mg/m<sup>2</sup> basis).</p><p>Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m<sup>2</sup> basis).</p><p><u>Environmental Risk Assessment (ERA)</u><br />The use of Epitam in accordance with the product information is not likely to result in an unacceptable environmental impact (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Epitam 250 mg, 500 mg and 750 mg film coated tablet:</u><br />Tablet core: croscarmellose sodium, Povidone k-30, microcrystalline cellulose, magnesium stearate.<br />Film-coating: Opadry white, colourants*.<br />* The colourants are:<br />500 mg tablet: iron oxide yellow (E172)<br />750 mg tablet: iron oxide yellow, iron oxide red (E172)</p><p><u>Epitam 100 mg/ml, oral solution</u><br />Sorbitol Solution; Glycerol; Acesulfame Pottasium; Trisodium Citrate Anhydrous treated; Methyl Paraben; Propyl Paraben; Citric Acid anhydrous; Concord Grape liquid flavor; Deionized water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablets and oral solution:</em><br />Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets: 3 years.

Oral Solution: 3 years.

After first opening: 7 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablets:</em><br />Do not store above 30&deg;C.</p><p><em>Oral solution:</em><br />Do not store above 30&deg;C.</p><p>Store in the original container in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablets:</em><br />Pack size: 30 tablets.</p><p><em>Oral Solution:</em><br />The 150 ml glass bottle of Epitam is packed in a cardboard box containing a 5 ml oral syringe (graduated every 0.1 ml) and an adaptor for the syringe.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablets and oral solution</em><br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI)
Riyadh, Saudi Arabia
11666 Riyadh, P.O.Box 106229
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04 April 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>